Summary
Signal counts
Assets tracked: 5
Watchlist assets: 1
Registry stop assets: 1
Sponsor overview
Merck Sharp & Dohme
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07227597 | https://clinicaltrials.gov/study/NCT07405151 | https://clinicaltrials.gov/study/NCT06818643 | https://clinicaltrials.gov/study/NCT06941272 | https://clinicaltrials.gov/study/NCT04479436 | https://clinicaltrials.gov/study/NCT06686394 | https://clinicaltrials.gov/study/NCT06780085 | https://clinicaltrials.gov/study/NCT06843447
Assets
Linked programs
- Gocatamig: Low Signal (1/5)
- I-DXd: Low Signal (1/5)
- MK-3120: Low Signal (1/5)
- Patritumab Deruxtecan: Registry Stop Signal (4/5)
- Raludotatug Deruxtecan: Low Signal (1/5)